CN116077727A - 一种具有三级嵌套结构的导电纤维束复合水凝胶材料及其制备方法 - Google Patents
一种具有三级嵌套结构的导电纤维束复合水凝胶材料及其制备方法 Download PDFInfo
- Publication number
- CN116077727A CN116077727A CN202310039891.0A CN202310039891A CN116077727A CN 116077727 A CN116077727 A CN 116077727A CN 202310039891 A CN202310039891 A CN 202310039891A CN 116077727 A CN116077727 A CN 116077727A
- Authority
- CN
- China
- Prior art keywords
- composite
- fiber
- conductive
- sodium alginate
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 136
- 239000002131 composite material Substances 0.000 title claims abstract description 98
- 239000000463 material Substances 0.000 title claims abstract description 43
- 239000000017 hydrogel Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 44
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 44
- 239000000661 sodium alginate Substances 0.000 claims abstract description 44
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 44
- 239000000243 solution Substances 0.000 claims abstract description 43
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 42
- 238000011065 in-situ storage Methods 0.000 claims abstract description 35
- 229920001940 conductive polymer Polymers 0.000 claims abstract description 32
- 229920001690 polydopamine Polymers 0.000 claims abstract description 32
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 27
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 24
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960003638 dopamine Drugs 0.000 claims abstract description 21
- 210000003007 myelin sheath Anatomy 0.000 claims abstract description 16
- 239000007983 Tris buffer Substances 0.000 claims abstract description 15
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000178 monomer Substances 0.000 claims abstract description 13
- 229910001961 silver nitrate Inorganic materials 0.000 claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 9
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- 239000011248 coating agent Substances 0.000 claims abstract description 7
- 238000000576 coating method Methods 0.000 claims abstract description 7
- 239000002019 doping agent Substances 0.000 claims abstract description 6
- 239000000499 gel Substances 0.000 claims abstract description 5
- 238000002166 wet spinning Methods 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 22
- 239000008367 deionised water Substances 0.000 claims description 16
- 229910021641 deionized water Inorganic materials 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical group [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000000502 dialysis Methods 0.000 claims description 12
- 230000015271 coagulation Effects 0.000 claims description 10
- 238000005345 coagulation Methods 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 239000003999 initiator Substances 0.000 claims description 9
- 238000004804 winding Methods 0.000 claims description 9
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 8
- 229910001424 calcium ion Inorganic materials 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000002657 fibrous material Substances 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 6
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 6
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 235000002949 phytic acid Nutrition 0.000 claims description 6
- 229940068041 phytic acid Drugs 0.000 claims description 6
- 239000000467 phytic acid Substances 0.000 claims description 6
- 239000001632 sodium acetate Substances 0.000 claims description 6
- 235000017281 sodium acetate Nutrition 0.000 claims description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 6
- 235000011152 sodium sulphate Nutrition 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 238000001879 gelation Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 238000000520 microinjection Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 238000000016 photochemical curing Methods 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 claims description 3
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 claims description 2
- 239000002262 Schiff base Substances 0.000 claims description 2
- 150000004753 Schiff bases Chemical class 0.000 claims description 2
- 238000002242 deionisation method Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 claims description 2
- 238000010526 radical polymerization reaction Methods 0.000 claims description 2
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 238000013016 damping Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000005470 impregnation Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 abstract description 14
- 230000008439 repair process Effects 0.000 abstract description 8
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 230000001112 coagulating effect Effects 0.000 abstract 1
- 238000007654 immersion Methods 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229920000767 polyaniline Polymers 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000012620 biological material Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000001723 curing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002322 conducting polymer Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010094 polymer processing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M11/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
- D06M11/83—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with metals; with metal-generating compounds, e.g. metal carbonyls; Reduction of metal compounds on textiles
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/19—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with synthetic macromolecular compounds
- D06M15/37—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- D06M15/61—Polyamines polyimines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M2101/00—Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
- D06M2101/02—Natural fibres, other than mineral fibres
- D06M2101/04—Vegetal fibres
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种具有三级嵌套结构的导电纤维束复合水凝胶材料及其制备方法。其制备方法包括:①配制海藻酸钠溶液结合湿法纺丝在高Ca2+凝固浴中制备海藻酸钠纤维;②将所得纤维浸渍于导电聚合物单体/掺杂剂混合水溶液中原位聚合;③再浸渍于多巴胺/Tris缓冲液(pH=8.5)中原位自聚合;④避光条件下,将得到的海藻酸钠/导电聚合物/聚多巴胺复合纤维浸渍于硝酸银溶液中进行反应引入纳米银涂层;⑤然后进行第二次多巴胺原位聚合,得到具有多层髓鞘结构的复合导电纤维;⑥将上述纤维进行加捻和复捻得到复合纤维束,并在外侧嵌套凝胶外膜得到导电复合水凝胶材料。该材料具有优异的生物相容性、导电和抗感染性能,可用于脊髓损伤修复等领域。
Description
技术领域
本发明涉及生物医用材料领域,具体涉及一种具有三级嵌套结构的导电纤维束复合水凝胶材料及其制备方法。
背景技术
脊髓损伤是脊柱损伤最严重的并发症,往往导致损伤节段以下肢体严重的功能障碍。据2019年相关资料显示,美国共有27万脊髓损伤患者,我国脊髓损伤流行病学统计数据比较离散,估计SCI患者在200万人左右。脊髓损伤不仅会给患者本人带来身体和心理的严重伤害,还会对整个社会造成巨大的经济负担。由于脊髓损伤所导致的社会经济损失,针对脊髓损伤的预防、治疗和康复已成为当今医学界的一大课题。
近年来,随着组织工程技术的迅速发展,各类用于脊髓损伤修复的生物材料如雨后春笋,而电信号的传导对于促进神经元的再生表现出非常独特的作用。导电聚合物作为一种新型功能材料,已经在脊髓损伤修复、神经修复等领域得到了广泛的研究。但是一方面天然脊髓组织在外形结构以及细胞分布具有一定的空间顺序,而且在神经元之间有电信号传递,简单的填充导电聚合物材料,无法得到优异的修复效果;另一方面,导电聚合物的生物相容性一般,且可加工性较差。
而且,由于导电聚合物在高温条件下极易氧化,导致其无法通过高温高压灭菌,简单的紫外灭菌或75%酒精灭菌的方法使得在通过手术植入生物材料进行修复的同时,往往易在手术过程中引入细菌,造成手术部位的感染。
因此,结合上述背景,本发明以纤维的形式制备一种可用于脊髓修复的生物材料。一方面克服导电聚合物加工难题,另一方面模拟脊髓的仿生三维结构以顺利恢复脊髓神经电信号的传导,同时以多层结构的形式引入多巴胺和纳米银,解决生物相容性和感染的问题。
发明内容
本发明的目的是针对神经和脊髓损伤临床问题,提供一种具有三级嵌套结构的导电纤维束复合水凝胶材料及其制备方法,所述材料有望用于脊髓损伤修复,同时解决伴随的组织感染问题。
本发明采用以下技术方案实现:
该材料为一种具有三级嵌套结构的导电纤维束复合水凝胶材料,具体制备步骤如下:
1)将海藻酸钠配制成一定浓度的溶液,使用微量注射泵注射到高浓度Ca2+凝固浴中,并通过纤维缠绕收集装置进行收集;
2)将步骤1)中的缠绕收集装置上的海藻酸钠纤维(不去除游离钙离子,保证纤维不会在聚合过程中降解),转移到旋转装置上(可以将上述纤维单层有序缠绕于旋转装置),连同装置浸渍于导电聚合物单体/掺杂剂复合水溶液中一定时间,加入引发剂引发导电聚合物单体在纤维表面原位聚合得到海藻酸钠/
导电聚合物复合纤维,反应结束后使用去离子透析去除单体等杂质;
3)将步骤2)中得到的复合纤维连同旋转装置浸渍于多巴胺/Tris缓冲液(pH=8.5)中进行原位自聚合,得到海藻酸钠/导电聚合物/聚多巴胺复合纤维,去离子水透析;
4)在避光条件下,将步骤3)中的复合纤维连同旋转装置浸渍于硝酸银溶液中,通过聚多巴胺的还原作用在纤维表面得到纳米银涂层,去离子水透析;
5)将步骤4)中得到的复合纤维连同旋转装置浸渍于多巴胺/Tris缓冲液(pH=8.5)中进行二次原位自聚合,经过冲洗、烘干等后处理工序后,最终得到具有多层髓鞘结构的海藻酸钠/导电聚合物/聚多巴胺/纳米银/聚多巴胺复合导电纤维材料;
6)将上述复合导电纤维加捻成束后,嵌套于透明圆柱形模具中央,上下端进行固定(保证纤维束不散),下端进行密封,从上端注射水凝胶预溶液,使溶液进行原位固化/光固化,得到嵌套有水凝胶外膜的复合导电纤维束材料。
进一步的,所述步骤1)中海藻酸钠粘度(10g/L,20℃)为0.02-0.1Pa·s,海藻酸钠溶液浓度为2-6wt%;钙离子凝固浴成分为5-20wt%氯化钙,0.5-3wt%硫酸钠,0.5-3wt%醋酸钠,其溶剂体系为乙醇和水的混合溶液,其中乙醇:水的体积比例可以是70:30,60:40,50:50,40:60,30:70等中的一种;微量注射泵注射速率为5-15ml/min,注射孔径为150-500微米;收集装置转速为50-150转/分钟;
进一步的,所述步骤2)中的导电聚合物单体为苯胺、吡咯、噻吩及其衍生物中的一种或几种,浓度为0.01-0.1wt%;掺杂剂包括植酸、盐酸等,浓度为5-10wt%;引发剂包括过硫酸铵、过硫酸钠、过硫酸钾等中的一种或几种,用量为0.5-1.5wt%;浸渍时间为0.5-4小时;旋转装置转速为30-60转/分钟;聚合时间为4-8h;
进一步的,所述步骤3)和步骤5)中多巴胺浓度为2-8mg/ml,反应时间为8-72小时;旋转装置转速为30-60转/分钟;
进一步的,所述步骤4)中硝酸银浓度为0.10-0.30mol/L,反应时间为8-72小时;旋转装置转速为30-60转/分钟;
进一步的,所述步骤6)中的复合导电纤维一般采用2-4根纤维加捻成束,再将2-4根纤维束进行复捻得到所需复合纤维束;水凝胶预溶液为GelMA、ChiMA、AlgMA、氧化透明质酸/Gelatin等中的一种或几种,其中氧化透明质酸/Gelatin采用席夫碱反应进行原位凝胶化,GelMA、ChiMA、AlgMA、HAMA等采用原位光固化进行凝胶,聚合物浓度为5-20wt%,如需光引发则光引发剂为LAP、IC-2959和VA086等中的一种或几种,引发剂浓度为0.01-0.05wt%,光固化时间为2-60分钟。
相对于现有技术,本发明具有以下优点/创新点:
1)通过多步法(湿法纺丝+原位自由基聚合+自聚合+氧化还原反应+自聚合+原位凝胶化嵌套),以海藻酸钠、钙盐、导电聚合物单体、掺杂剂、多巴胺、硝酸银等作为原料,制备了一种具有多层髓鞘结构的海藻酸钠/导电聚合物/聚多巴胺/纳米银/聚多巴胺复合导电纤维材料(一级结构),再对上述纤维进行加捻、复捻后得到具有轴向螺旋排列结构的复合纤维束(二级结构),然后进一步结合原位凝胶化工艺将水凝胶外膜嵌套在纤维束外侧,对“二级结构”进行包裹固定,形成“三级结构”。该材料同时具备导电性能、抗菌性能、高拉伸强度、高生物相容性、可生物降解性能。本发明在原料、工艺以及结构上实现创新;
2)本发明中通过原料选择、制备工艺调控、结构设计,实现各种原料特性的有机协同增效:选取高分子量的海藻酸钠和高浓度钙离子凝固浴,多层复合结构(微观多重网络结构和宏观多层髓鞘结构)以及最后的烘干工艺(干燥过程中对于纤维的牵伸作用),赋予纤维以高拉伸强度;导电聚合物和掺杂剂的配合,实现纤维的高导电;双层多巴胺实现纳米银的合成(还原)与稳定,第一层聚多巴胺作为纳米银形成的位点,第二层聚多巴胺包裹纳米银,延缓纳米银的释放,减小其毒性,并提升材料的生物相容性;最外面的凝胶外膜采用GelMA等具有高生物相容性、可降解、光固化或自交联功能的原料,以原位固定纤维束的结构;
3)该复合导电纤维材料植入体内后,通过轴向排列的导电聚合物纤维束实现对脊髓结构的仿生模拟,可以通过外接电源或者利用生物体自身的生物电信号,实现对电刺激的定向传导,实现脊髓损伤修复,同时还可以解决伴随的感染问题。
附图说明
图1为一种具有多层髓鞘结构的复合导电纤维结构示意图;
图2为多层髓鞘结构的复合导电纤维通过加捻和复捻工艺形成复合纤维束的示意图;
图3为复合导电纤维束嵌套凝胶外膜的脊髓损伤修复材料结构示意图。
具体实施方式
下面结合附图及具体实例进一步说明本发明技术方案。
实施例1:
1)配制4wt%海藻酸钠溶液,使用微量注射泵注射(注射速率为10ml/min,注射孔径为200微米)到Ca2+凝固浴(10wt%氯化钙,0.5wt%硫酸钠,0.5wt%醋酸钠,乙醇:水=50:50(v:v)的混合溶液)中,并通过纤维缠绕收集装置进行收集(收集速率为50转/分钟);
2)将步骤1)中的缠绕收集装置上的海藻酸钠纤维(不去除游离钙离子),转移到旋转装置上,连同装置浸渍于苯胺/植酸复合水溶液(0.05wt%/5wt%)中30min,旋转速率为30转/分钟,加入过硫酸铵引发剂(0.5wt%)引发苯胺在纤维表面原位聚合4小时得到海藻酸钠/导电聚合物复合纤维,反应结束后使用去离子水透析去除单体等杂质;
3)将步骤2)中得到的复合纤维连同旋转装置浸渍于2mg/ml多巴胺/Tris缓冲液(pH=8.5)中进行原位自聚合12小时,旋转速度为30转/分钟,得到海藻酸钠/导电聚合物/聚多巴胺复合纤维,去离子水透析;
4)在避光条件下,将步骤3)中的复合纤维连同旋转装置浸渍于硝酸银溶液中(0.10mol/L),反应8小时,旋转速率为30转/分钟,通过聚多巴胺的还原作用在纤维表面得到纳米银涂层,去离子水透析;
5)将步骤4)中得到的复合纤维连同旋转装置浸渍于2mg/ml多巴胺/Tris缓冲液(pH=8.5)中进行二次原位自聚合12小时,经过冲洗、37℃低温烘干等后处理工序后,最终得到具有多层髓鞘结构的海藻酸钠/聚苯胺/聚多巴胺/纳米银/聚多巴胺复合导电纤维材料;
6)将上述4根复合导电纤维加捻成纤维束后,4根纤维束复捻形成复合纤维束,嵌套于透明圆柱形模具中央,上下端使用夹具进行固定(保证复合纤维束不散),下端进行密封,从上端注射GelMA/LAP水凝胶预溶液(PBS溶剂,浓度为10wt%/0.25wt%),使溶液进行原位固化/光固化5分钟,去除模具得到嵌套有水凝胶外膜的复合导电纤维束材料。
7)具有多层髓鞘结构的导电纤维直径为126.4微米,该水凝胶材料的电导率为3.1S/cm,材料浸提液CCK-8结果存活率为96.3%,银24小时的释放浓度为0.421mg/mL,材料抑菌圈效果明显,28天降解56.1%。
实施例2:
1)配制4wt%海藻酸钠溶液,使用微量注射泵注射(注射速率为10ml/min,注射孔径为200微米)到Ca2+凝固浴(10wt%氯化钙,0.5wt%硫酸钠,0.5wt%醋酸钠,乙醇:水=50:50的混合溶液)中,并通过纤维缠绕收集装置进行收集(收集速率为50转/分钟);
2)将步骤1)中的缠绕收集装置上的海藻酸钠纤维(不去除游离钙离子),转移到旋转装置上,连同装置浸渍于苯胺/植酸复合水溶液(0.10wt%/7.5wt%)中30min,旋转速率为30转/分钟,加入过硫酸铵引发剂(0.75wt%)引发苯胺在纤维表面原位聚合8小时得到海藻酸钠/导电聚合物复合纤维,反应结束后使用去离子水透析去除单体等杂质;
3)将步骤2)中得到的复合纤维连同旋转装置浸渍于2mg/ml多巴胺/Tris缓冲液(pH=8.5)中进行原位自聚合12小时,旋转速度为30转/分钟,得到海藻酸钠/导电聚合物/聚多巴胺复合纤维,去离子水透析;
4)在避光条件下,将步骤3)中的复合纤维连同旋转装置浸渍于硝酸银溶液中(0.10mol/L),反应8小时,旋转速率为30转/分钟,通过聚多巴胺的还原作用在纤维表面得到纳米银涂层,去离子水透析;
5)将步骤4)中得到的复合纤维连同旋转装置浸渍于2mg/ml多巴胺/Tris缓冲液(pH=8.5)中进行二次原位自聚合12小时,经过冲洗、37℃低温烘干等后处理工序后,最终得到具有多层髓鞘结构的海藻酸钠/聚苯胺/聚多巴胺/纳米银/聚多巴胺复合导电纤维材料;
6)将上述4根复合导电纤维加捻成纤维束后,4根纤维束复捻形成复合纤维束,嵌套于透明圆柱形模具中央,上下端使用夹具进行固定(保证复合纤维束不散),下端进行密封,从上端注射GelMA/LAP水凝胶预溶液(PBS溶剂,浓度为10wt%/0.25wt%),使溶液进行原位固化/光固化5分钟,去除模具得到嵌套有水凝胶外膜的复合导电纤维束材料。
7)相比于实施例1,苯胺浓度提升,聚合时间增加,具有多层髓鞘结构的导电纤维直径为131.6微米,该水凝胶材料的电导率为4.2S/cm,材料浸提液CCK-8结果存活率为94.1%,银24小时的释放浓度为0.452mg/mL材料抑菌圈效果明显,28天降解49.5%。
实施例3:
1)配制6wt%海藻酸钠溶液,使用微量注射泵注射(注射速率为10ml/min,注射孔径为400微米)到Ca2+凝固浴(20wt%氯化钙,1.0wt%硫酸钠,1.0wt%醋酸钠,乙醇:水=30:70(v:v)的混合溶液)中,并通过纤维缠绕收集装置进行收集(收集速率为50转/分钟);
2)将步骤1)中的缠绕收集装置上的海藻酸钠纤维(不去除游离钙离子),转移到旋转装置上,连同装置浸渍于苯胺/植酸复合水溶液(0.05wt%/5wt%)中30min,旋转速率为30转/分钟,加入过硫酸铵引发剂(0.5wt%)引发苯胺在纤维表面原位聚合4小时得到海藻酸钠/导电聚合物复合纤维,反应结束后使用去离子水透析去除单体等杂质;
3)将步骤2)中得到的复合纤维连同旋转装置浸渍于2mg/ml多巴胺/Tris缓冲液(pH=8.5)中进行原位自聚合12小时,旋转速度为30转/分钟,得到海藻酸钠/导电聚合物/聚多巴胺复合纤维,去离子水透析;
4)在避光条件下,将步骤3)中的复合纤维连同旋转装置浸渍于硝酸银溶液中(0.10mol/L),反应8小时,旋转速率为30转/分钟,通过聚多巴胺的还原作用在纤维表面得到纳米银涂层,去离子水透析;
5)将步骤4)中得到的复合纤维连同旋转装置浸渍于2mg/ml多巴胺/Tris缓冲液(pH=8.5)中进行二次原位自聚合12小时,经过冲洗、37℃低温烘干等后处理工序后,最终得到具有多层髓鞘结构的海藻酸钠/聚苯胺/聚多巴胺/纳米银/聚多巴胺复合导电纤维材料;
6)将上述4根复合导电纤维加捻成纤维束后,4根纤维束复捻形成复合纤维束,嵌套于透明圆柱形模具中央,上下端使用夹具进行固定(保证复合纤维束不散),下端进行密封,从上端注射GelMA/LAP水凝胶预溶液(PBS溶剂,浓度为10wt%/0.25wt%),使溶液进行原位固化/光固化5分钟,得到嵌套有水凝胶外膜的复合导电纤维束材料。
7)相比于实施例1,海藻酸钠浓度提升,凝固浴中Ca2+浓度提升,纺丝孔口径增大,具有多层髓鞘结构的导电纤维的直径为241.3微米,该水凝胶材料的电导率为2.4S/cm,材料浸提液CCK-8结果存活率为95.4%,银24小时的释放浓度为0.538mg/mL,材料抑菌圈效果明显,28天降解62.4%。
实施例4:
1)配制4wt%海藻酸钠溶液,使用微量注射泵注射(注射速率为10ml/min,注射孔径为200微米)到Ca2+凝固浴(10wt%氯化钙,0.5wt%硫酸钠,0.5wt%醋酸钠,乙醇:水=50:50(v:v)的混合溶液)中,并通过纤维缠绕收集装置进行收集(收集速率为50转/分钟);
2)将步骤1)中的缠绕收集装置上的海藻酸钠纤维(不去除游离钙离子),转移到旋转装置上,连同装置浸渍于苯胺/植酸复合水溶液(0.05wt%/5wt%)中30min,旋转速率为30转/分钟,加入过硫酸铵引发剂(0.5wt%)引发苯胺在纤维表面原位聚合4小时得到海藻酸钠/导电聚合物复合纤维,反应结束后使用去离子水透析去除单体等杂质;
3)将步骤2)中得到的复合纤维连同旋转装置浸渍于4mg/ml多巴胺/Tris缓冲液(pH=8.5)中进行原位自聚合48小时,旋转速度为30转/分钟,得到海藻酸钠/导电聚合物/聚多巴胺复合纤维,去离子水透析;
4)在避光条件下,将步骤3)中的复合纤维连同旋转装置浸渍于硝酸银溶液中(0.10mol/L),反应8小时,旋转速率为30转/分钟,通过聚多巴胺的还原作用在纤维表面得到纳米银涂层,去离子水透析;
5)将步骤4)中得到的复合纤维连同旋转装置浸渍于4mg/ml多巴胺/Tris缓冲液(pH=8.5)中进行二次原位自聚合48小时,经过冲洗、37℃低温烘干等后处理工序后,最终得到具有多层髓鞘结构的海藻酸钠/聚苯胺/聚多巴胺/纳米银/聚多巴胺复合导电纤维材料;
6)将上述4根复合导电纤维加捻成纤维束后,4根纤维束复捻形成复合纤维束,嵌套于透明圆柱形模具中央,上下端使用夹具进行固定(保证复合纤维束不散),下端进行密封,从上端注射GelMA/LAP水凝胶预溶液(PBS溶剂,浓度为10wt%/0.25wt%),使溶液进行原位固化/光固化5分钟,去除模具得到嵌套有水凝胶外膜的复合导电纤维束材料。
7)相比于实施例1,多巴胺浓度提高,聚合时间延长,具有多层髓鞘结构的导电纤维直径为131.2微米,该水凝胶材料的电导率为2.74S/cm,材料浸提液CCK-8结果存活率为97.4%,银24小时的释放浓度为0.449mg/mL,材料抑菌圈效果明显,28天降解54.7%。
Claims (7)
1.一种具有三级嵌套结构的导电纤维束复合水凝胶材料,其特征在于:所述复合水凝胶材料是以具有多层髓鞘结构的复合导电纤维为一级结构,经加捻和复捻得到复合纤维束二级结构,在外侧嵌套凝胶外膜得到具有三级嵌套结构的导电纤维束复合水凝胶材料;所述具有多层髓鞘结构的复合导电纤维是首先使用海藻酸钠溶液结合湿法纺丝工艺制得海藻酸钠纤维,再使用原位自由基聚合工艺制得海藻酸钠/导电聚合物复合纤维,然后使用多巴胺-Tris缓冲溶液引入聚多巴胺层,并利用聚多巴胺对于硝酸银的还原作用引入纳米银层,最后二次引入聚多巴胺层得到。
2.如权利要求1所述的一种具有三级嵌套结构的导电纤维束复合水凝胶材料,其特征在于:其制备方法包括如下步骤:
1)将海藻酸钠配制成溶液,使用微量注射泵注射到高浓度Ca2+凝固浴中,并通过纤维缠绕收集装置进行收集;
2)直接将步骤1)中的缠绕收集装置上的海藻酸钠纤维转移到旋转装置上,一同浸渍于导电聚合物单体/掺杂剂复合水溶液中,加入引发剂引发导电聚合物单体在纤维表面原位聚合得到海藻酸钠/导电聚合物复合纤维,反应结束后使用去离子透析去除杂质;
3)将步骤2)中得到的复合纤维连同旋转装置浸渍于多巴胺/Tris缓冲液(pH=8.5)中进行原位自聚合,得到海藻酸钠/导电聚合物/聚多巴胺复合纤维,去离子水透析;
4)在避光条件下,将步骤3)获得的复合纤维连同旋转装置浸渍于硝酸银溶液中,通过聚多巴胺的还原作用在纤维表面得到纳米银涂层,去离子水透析;
5)将步骤4)中得到的复合纤维连同旋转装置浸渍于多巴胺/Tris缓冲液(pH=8.5)中进行二次原位自聚合,经过冲洗、烘干后,得到具有多层髓鞘结构的海藻酸钠/导电聚合物/聚多巴胺/纳米银/聚多巴胺复合导电纤维材料;
6)将上述复合导电纤维加捻成束后,嵌套于透明圆柱形模具中央,上下端进行固定以保证纤维束不,一端进行密封,从另一端注射水凝胶预溶液,使溶液进行固化,从而在复合导电纤维表面嵌套水凝胶外膜,去除模具得到具有三级嵌套结构的导电纤维束复合水凝胶材料。
3.如权利要求2所述的一种具有三级嵌套结构的导电纤维束复合水凝胶材料,其特征在于:步骤1)中海藻酸钠粘度(10g/L,20℃)为0.02-0.1Pa·s,海藻酸钠溶液浓度为2-6wt%;钙离子凝固浴成分为5-20wt%氯化钙,0.5-3wt%硫酸钠,0.5-3wt%醋酸钠,其溶剂体系为乙醇和水的混合溶液;微量注射泵注射速率为5-15ml/min,注射孔径为150-500微米;收集装置转速为50-150转/分钟。
4.如权利要求2所述的一种具有三级嵌套结构的导电纤维束复合水凝胶材料,其特征在于:步骤2)中的导电聚合物单体为苯胺、吡咯、噻吩及其衍生物中的一种或几种,浓度为0.01-0.1wt%;掺杂剂为植酸、盐酸重的一种或几种,浓度为5-10wt%;引发剂为过硫酸铵、过硫酸钠、过硫酸钾中的一种或几种,用量为0.5-1.5wt%;浸渍时间为0.5-4小时;旋转装置转速为30-60转/分钟;聚合时间为4-8小时。
5.如权利要求2所述的一种具有三级嵌套结构的导电纤维束复合水凝胶材料,其特征在于:步骤3)和步骤5)中多巴胺/Tris缓冲液中多巴胺浓度为2-8mg/ml,反应时间为8-72小时;旋转装置转速为30-60转/分钟。
6.如权利要求2所述的一种具有三级嵌套结构的导电纤维束复合水凝胶材料,其特征在于:步骤4)中硝酸银溶液浓度为0.10-0.30mol/L,反应时间为8-72小时;旋转装置转速为30-60转/分钟。
7.如权利要求2所述的一种具有三级嵌套结构的导电纤维束复合水凝胶材料,其特征在于:步骤6)中的采用2-4根复合导电纤维加捻成束,再将2-4根纤维束进行复捻得到复合纤维束;水凝胶预溶液为GelMA、ChiMA、AlgMA、HAMA、氧化透明质酸/Gelatin中的一种或几种,其中氧化透明质酸/Gelatin采用席夫碱反应进行原位凝胶化,GelMA、ChiMA、AlgMA、HAMA采用原位光固化进行凝胶。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310039891.0A CN116077727B (zh) | 2023-01-13 | 2023-01-13 | 一种具有三级嵌套结构的导电纤维束复合水凝胶材料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310039891.0A CN116077727B (zh) | 2023-01-13 | 2023-01-13 | 一种具有三级嵌套结构的导电纤维束复合水凝胶材料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116077727A true CN116077727A (zh) | 2023-05-09 |
CN116077727B CN116077727B (zh) | 2025-03-18 |
Family
ID=86211672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310039891.0A Active CN116077727B (zh) | 2023-01-13 | 2023-01-13 | 一种具有三级嵌套结构的导电纤维束复合水凝胶材料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116077727B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116870263A (zh) * | 2023-09-07 | 2023-10-13 | 四川省医学科学院·四川省人民医院 | 一种具有仿生层结构的角膜绷带镜及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060006295A (ko) * | 2004-07-15 | 2006-01-19 | 이진호 | 친수성 및 선택적 투과성을 가지는 다공성 신경유도관과이의 제조 방법 |
CN106730031A (zh) * | 2016-12-30 | 2017-05-31 | 清华大学 | 一种用于脊髓损伤修复的仿生纤维蛋白水凝胶束及其制备方法 |
CN110124113A (zh) * | 2019-05-29 | 2019-08-16 | 四川大学 | 取向导电胶原水凝胶、仿生导电神经支架材料及其制备方法 |
WO2020042043A1 (zh) * | 2018-08-29 | 2020-03-05 | 南通纺织丝绸产业技术研究院 | 一种负载光催化剂的微纳复合纤维材料及其制备方法 |
CN111001036A (zh) * | 2019-12-19 | 2020-04-14 | 北京大学人民医院(北京大学第二临床医学院) | 一种单壁碳纳米管复合材料导电神经套管及其制备方法与应用 |
CN114350199A (zh) * | 2021-12-07 | 2022-04-15 | 中山大学 | 一种导电复合水凝胶涂层神经电极及其制备方法和应用 |
CN115227866A (zh) * | 2022-08-15 | 2022-10-25 | 浙江大学 | 兼具组织黏附、多重杀菌和电刺激组织再生功能的可注射水凝胶伤口敷料及其制备方法 |
WO2022241150A2 (en) * | 2021-05-12 | 2022-11-17 | 206 Ortho, Inc. | Degradable composite and method of fabrication |
-
2023
- 2023-01-13 CN CN202310039891.0A patent/CN116077727B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060006295A (ko) * | 2004-07-15 | 2006-01-19 | 이진호 | 친수성 및 선택적 투과성을 가지는 다공성 신경유도관과이의 제조 방법 |
CN106730031A (zh) * | 2016-12-30 | 2017-05-31 | 清华大学 | 一种用于脊髓损伤修复的仿生纤维蛋白水凝胶束及其制备方法 |
WO2020042043A1 (zh) * | 2018-08-29 | 2020-03-05 | 南通纺织丝绸产业技术研究院 | 一种负载光催化剂的微纳复合纤维材料及其制备方法 |
CN110124113A (zh) * | 2019-05-29 | 2019-08-16 | 四川大学 | 取向导电胶原水凝胶、仿生导电神经支架材料及其制备方法 |
CN111001036A (zh) * | 2019-12-19 | 2020-04-14 | 北京大学人民医院(北京大学第二临床医学院) | 一种单壁碳纳米管复合材料导电神经套管及其制备方法与应用 |
WO2022241150A2 (en) * | 2021-05-12 | 2022-11-17 | 206 Ortho, Inc. | Degradable composite and method of fabrication |
CN114350199A (zh) * | 2021-12-07 | 2022-04-15 | 中山大学 | 一种导电复合水凝胶涂层神经电极及其制备方法和应用 |
CN115227866A (zh) * | 2022-08-15 | 2022-10-25 | 浙江大学 | 兼具组织黏附、多重杀菌和电刺激组织再生功能的可注射水凝胶伤口敷料及其制备方法 |
Non-Patent Citations (1)
Title |
---|
郑勰;周一凡;陈思远;刘晓云;查刘生;: "刺激响应性电纺纳米纤维", 化学进展, no. 07, 24 July 2018 (2018-07-24) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116870263A (zh) * | 2023-09-07 | 2023-10-13 | 四川省医学科学院·四川省人民医院 | 一种具有仿生层结构的角膜绷带镜及其制备方法 |
CN116870263B (zh) * | 2023-09-07 | 2023-11-21 | 四川省医学科学院·四川省人民医院 | 一种具有仿生层结构的角膜绷带镜及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN116077727B (zh) | 2025-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kundu et al. | Cellulose hydrogels: Green and sustainable soft biomaterials | |
CN108912352A (zh) | 一种抗菌粘附可注射水凝胶敷料及其制备方法和应用 | |
CN110448721B (zh) | 一种抗菌粘附导电止血抗氧化的可注射复合水凝胶及其制备方法和应用 | |
CN103341214A (zh) | 一种丝素蛋白膜及其制备方法 | |
CN108014376A (zh) | 一种甜菜碱修饰壳聚糖的多糖水凝胶及其制备方法 | |
CN110201219A (zh) | 一种可注射且快速凝胶化的复合水凝胶及其制备方法 | |
RU2621114C2 (ru) | Полисахаридные волокна для раневых повязок | |
CN108785738A (zh) | 一种水凝胶医用敷料的制备方法及其应用 | |
CN104721875A (zh) | 一种亲水型硅橡胶医用敷料及其制备方法 | |
CN114699564B (zh) | 一种粘附力增强的润滑涂层、其应用和一种医用介入类导管 | |
CN113638078B (zh) | 一种聚电解质复合物水凝胶纤维及其制备方法 | |
CN116077727A (zh) | 一种具有三级嵌套结构的导电纤维束复合水凝胶材料及其制备方法 | |
CN106620832A (zh) | 一种透明抗菌水凝胶敷料、其制备方法和应用 | |
CN109675134A (zh) | 一种血液透析器的抗凝改性方法及其应用 | |
CN110152055A (zh) | 海藻酸胺化衍生物/细菌纤维素纳米晶复合凝胶构筑的功能性药物缓释医用敷料 | |
CN108250463A (zh) | 一种纳米纤维素/海藻酸钠导电水凝胶的制备方法 | |
CN104873467B (zh) | 一种生物降解型互穿网络聚合物微球的制备方法 | |
Aneem et al. | Investigation of coagulation process of wet-spun sodium alginate polymannuronate fibers with varied functionality using organic coagulants and cross-linkers | |
CN111424425B (zh) | 血管外科用纳米止血抗菌复合材料及其制备方法 | |
CN108219083A (zh) | 一种葡萄籽蛋白基水凝胶及其制备方法和应用 | |
CN112442193B (zh) | 一种兼具韧性与粘附性的自修复仿生水凝胶的制备方法 | |
CN111493863B (zh) | 透气抗菌电极片及其制备方法 | |
CN101766836B (zh) | 纳米银脊髓及外周神经损伤修复材料的制备工艺 | |
CN107456602A (zh) | 一种全生物可降解短纤增强的医用水凝胶体敷料及其制备方法 | |
CN110180023A (zh) | 一种高强度生物质组织工程支架材料的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |